Abstract:Hepatic steatosis is the beginning phase of nonalcoholic fatty liver disease, and hyperhomocysteinemia (HHcy) is a significant risk factor. Soluble epoxide hydrolase (sEH) hydrolyzes epoxyeicosatrienoic acids (EETs) and other epoxy fatty acids, attenuating their cardiovascular protective effects. However, the involvement of sEH in HHcy-induced hepatic steatosis is unknown. The current study aimed to explore the role of sEH in HHcy-induced lipid disorder. We fed 6-wk-old male mice a chow diet or 2% (wt/wt) high-metnionine diet for 8 wk to establish the HHcy model. A high level of homocysteine induced lipid accumulation in vivo and in vitro, which was concomitant with the increased activity and expression of sEH. Treatment with a highly selective specific sEH inhibitor (0.8 mg·kg-1·day-1 for the animal model and 1 μM for cells) prevented HHcy-induced lipid accumulation in vivo and in vitro. Inhibition of sEH activated the peroxisome proliferator-activated receptor-α (PPAR-α), as evidenced by elevated β-oxidation of fatty acids and the expression of PPAR-α target genes in HHcy-induced hepatic steatosis. In primary cultured hepatocytes, the effect of sEH inhibition on PPAR-α activation was further confirmed by a marked increase in PPAR-response element luciferase activity, which was reversed by knock down of PPAR-α. Of note, 11,12-EET ligand dependently activated PPAR-α. Thus increased sEH activity is a key determinant in the pathogenesis of HHcy-induced hepatic steatosis, and sEH inhibition could be an effective treatment for HHcy-induced hepatic steatosis. NEW & NOTEWORTHY In the current study, we demonstrated that upregulation of soluble epoxide hydrolase (sEH) is involved in the hyperhomocysteinemia (HHcy)-caused hepatic steatosis in an HHcy mouse model and in murine primary hepatocytes. Improving hepatic steatosis in HHcy mice by pharmacological inhibition of sEH to activate peroxisome proliferator-activated receptor-α was ligand dependent, and sEH could be a potential therapeutic target for the treatment of nonalcoholic fatty liver disease.

PROTAC-Mediated Selective Degradation of Cytosolic Soluble Epoxide Hydrolase Enhances ER Stress Reduction

In vivo-Active Soluble Epoxide Hydrolase-targeting PROTACs with Improved Potency and Stability

STRUCTURE-BASED DESIGN OF PROTACS FOR THE DEGRADATION OF SOLUBLE EPOXIDE HYDROLASE

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Degradation Versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase

Discovery and Characterization of Active CBP/EP300 Degraders Targeting the HAT Domain

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

Soluble Epoxide Hydrolase: A Potential Target for Metabolic Diseases

Soluble Epoxide Hydrolase: A Potential Target for Metabolic Diseases.

Simultaneous Inhibition Of Sirt2 Deacetylase And Defatty-Acylase Activities Via A Protac Strategy

Selective Protein of Interest Degradation Through the Split-and-Mix Liposome Proteolysis Targeting Chimera Approach.

Phase Separation Enhanced PROTAC for Highly Efficient Protein Degradation

Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

Dual-ligand PROTACS mediate superior target protein degradation in vitro and therapeutic efficacy in vivo

Design and characterization of a heterobifunctional degrader of KEAP1

Stimuli‐Responsive PROTACs for Controlled Protein Degradation

Inhibition of Soluble Epoxide Hydrolase Ameliorates Hyperhomocysteinemia-Induced Hepatic Steatosis by Enhancing Β-Oxidation of Fatty Acid in Mice.

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes